Cronos Group Inc.
NASDAQ:CRONDrug Manufacturers - Specialty & Generic
-$0.02 today
- Market cap
- $1.16B
- Beta
- 1.25
- P/E (TTM)
- -488.3
- EPS (TTM)
- -$0.01
Volume 1.13M
Average 1.51M
CRON Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Cronos Group Inc.NASDAQ: CRON
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $13.56M rose 75.6% year over year, ahead of the -88.4% change in trailing-twelve-month net income. Sequentially, it rose 456.3% from the prior quarter. Over 3 fiscal years it compounded at -74.1% a year.
Context
- Net income amounted to 2.0% of revenue in FY2025, down 32.1 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of $69.82M (+2483.7%) for the fiscal year ending Dec 2026, a step up from the -107.3% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $13.56M+456.3% QoQ
- Last fiscal yearDec 2025
- -$2.93M-107.3% YoY
- LTMMar 2026
- $5.84M-88.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +75.6% | +109.0% | +33.4 pp |
| 1 year | -107.3% | +2483.7% | +2591.0 pp |
| 3-year CAGR | -74.1% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (2.93M) USD
- Year-over-year change
- -107.3%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.93M) | -107.3% |
| FY2024 | 2024-12-31 | 40.02M | +153.7% |
| FY2023 | 2023-12-31 | (74.55M) | +55.8% |
| FY2022 | 2022-12-31 | (168.73M) | +57.5% |
| FY2021 | 2021-12-31 | (397.2M) | — |
Net Income vs competitors
How CRON compares with its peers on the latest reported figures
- CRON's LTM Mar 2026 net income of $5.84M is the 10th largest of the 11 companies compared; the peer median is $14.37M.
- Its year-over-year change of -88.4% is the lowest of 11, against a peer median of +52.7%.
- Net income amounts to 2.8% of revenue for CRON, versus a peer median of 27.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $294.88M | +220.5% | +13.6% | 42.0% | |
| LTM Mar 2026 | $157.3M | -54.5% | +3.8% | 76.8% | |
BBOTBridgeBio Oncology Therapeutics Inc. | LTM Mar 2026 | $154.1M | +1029.3% | +3264.4% | — |
| LTM Mar 2026 | $111.9M | +111.9% | -24.7% | 10.7% | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $107.28M | +34.6% | +118.7% | 536.4% |
| LTM Mar 2026 | $79.23M | -44.1% | +2.4% | 11.0% | |
| LTM Mar 2026 | $74.95M | +70.7% | — | 9.4% | |
| LTM Jun 2026 | $71.19M | -60.8% | +18.5% | 67.8% | |
| LTM Mar 2026 | $23.61M | +19.3% | +20.6% | 27.4% | |
| LTM Mar 2026 | $5.84M | -88.4% | -74.1% | 2.8% | |
| LTM Mar 2026 | $5.14M | +105.0% | -23.8% | 0.7% | |
| Peer median (excluding CRON) | $14.37M | +52.7% | +13.6% | 27.4% | |
Competitors are the stored peer set for CRON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (397.2M) | (168.73M) | (74.55M) | 40.02M | (2.93M) |
| Depreciation & Amortization | 15.4M | 13.12M | 8.11M | 9.34M | 14.48M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 10.15M | 15.12M | 8.77M | 8.7M | 7.05M |
| Change in Working Capital | (4.84M) | 15.66M | (26.47M) | (311K) | (35.02M) |
| Accounts Receivables | (12.16M) | (8.55M) | (6.59M) | (917K) | (26.2M) |
| Inventory | 11.57M | (7.22M) | 7.4M | 5.28M | (10.58M) |
| Accounts Payables | (1.6M) | (863K) | (773K) | (7.45M) | 1.13M |
| Other Working Capital | (2.65M) | 32.29M | (26.51M) | 2.77M | 636.96K |
| Other Non-Cash Items | 222.88M | 35.89M | 41.31M | (38.9M) | 42.73M |
| Operating Cash Flow | (153.62M) | (88.95M) | (42.84M) | 18.84M | 26.32M |
| Capital Expenditures | (12.26M) | (5.03M) | (3.42M) | (13.15M) | (26.17M) |
| Acquisitions (Net) | 0 | 0 | 0 | 5.71M | 2.9M |
| Purchases of Investments | (230M) | (271.38M) | (608.25M) | (8.34M) | (59.44M) |
| Sales of Investments | 215.3M | 268.87M | 532.84M | 181.9M | 5.15M |
| Other Investing Activities | (3.06M) | 4.12M | 18.42M | 8.41M | 0 |
| Investing Cash Flow | (28.9M) | (1.84M) | (59.5M) | 175.15M | (77.9M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (9.91M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (13.44M) | (2.9M) | (1.03M) | (1.23M) | (10.34M) |
| Financing Cash Flow | (13.44M) | (2.9M) | (1.03M) | (1.23M) | (20.25M) |
| Effect of Forex Changes | 4.91M | (28.64M) | 8.01M | (3.25M) | 3.89M |
| Net Change in Cash | (191.05M) | (122.33M) | (95.35M) | 189.51M | (67.94M) |
| Free Cash Flow | (165.88M) | (93.98M) | (46.26M) | 5.69M | 151.61K |
Cronos Group Inc.
NASDAQ:CRON
Intrinsic Alpha fair value
Locked
Current Price
$3.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.